🔬Biotech Firm Launches $350M Fund to Build Companies From Scratch
A new fund is betting big on biotech startups from scratch
TL;DR
A venture firm launched a $350 million fund to build biotech companies from the ground up. One-third of funds go into in-house projects, with AI playing a key role in drug discovery.
A new venture capital firm has launched a $350 million fund dedicated to building biotech startups from scratch. This isn't just about investing in existing ideas; it's about creating companies and technologies that don't yet exist. The firm is pioneering epigenetic gene editing, aiming for safer delivery methods to specific cells. Why does this matter? Because the pharma industry is facing a massive patent cliff, with record cash reserves from pandemic profits. Pharma giants like Eli Lilly are already making huge exits in antibody drug conjugates, buying up innovative startups left and right. The NIH budget has stagnated, but AI is stepping in to accelerate drug discovery at unprecedented speeds.
Key Points
The new fund has $350 million dedicated to building and funding biotech startups from scratch
Keep reading — it's free
Enter your email to keep reading — plus the best of AI & tech, daily. Free, forever.
Already a member? Sign in
Comments
Be the first to comment